Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 20,612 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Not listed No phase listed Observational

Impact of Tecfidera on Gut Microbiota

NCT02736279
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dimethyl fumarate
Drug
Lead sponsor
Virginia Simnad
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 25, 2026, 11:10 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Clovis, California • Los Angeles, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

NCT00430846
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
Interventions
SGN-35
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

NCT00392288
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
4 Years to 11 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

NCT00891046
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 25, 2026, 11:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Assessment in Newborns for Diabetes Autoimmunity

NCT00649246
View directory record Official record
Conditions
Type 1 Diabetes, Autoimmunity
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
Not listed
Enrollment
25,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

NCT00005988
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloma
Interventions
cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, in vitro-treated bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT01242488
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 25, 2026, 11:10 AM EDT
Withdrawn Phase 1 Interventional

Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)

NCT01316146
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions
CAR.CD30 T cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 25, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

CART-19 Post-ASCT for Multiple Myeloma

NCT02794246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CART-19 cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma
Interventions
BI 1744CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Lakewood, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00005792
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
etoposide phosphate, melphalan, topotecan, Autologous Stem Cell Rescue
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 69 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 25, 2026, 11:10 AM EDT
Completed No phase listed Observational

Effects of HIV and Hepatitis C Virus on the Brain

NCT00494936
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

NCT02970136
View directory record Official record
Conditions
Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions
OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 64 Years
Enrollment
754 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 25, 2026, 11:10 AM EDT
Active, not recruiting Phase 4 Interventional

Effects of Ocrevus in Relapsing Multiple Sclerosis

NCT04387734
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ocrelizumab, Platform
Drug
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Not applicable Interventional Results available

The BRIgHT Program: Building Resilience in HIV Together

NCT03673098
View directory record Official record
Conditions
Resilience, Psychological
Interventions
Adapted 3RP
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 25, 2026, 11:10 AM EDT
Not listed Not applicable Interventional

Effects of Spinal Cord Injury on Female Sexual Response

NCT00142714
View directory record Official record
Conditions
Female Sexual Dysfunction, Multiple Sclerosis, Spinal Cord Injury
Interventions
Sympathetic manipulation on sexual arousal in women
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 16, 2006 · Synced Oct 25, 2026, 11:10 AM EDT
Recruiting Phase 1 Interventional

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

NCT06465316
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography, Teclistamab
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Derby, Connecticut • Guilford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex

NCT00002004
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 11:10 AM EDT
Completed No phase listed Observational

iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy

NCT02564484
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Physician Performance Through Continuous Professional Development

NCT00115284
View directory record Official record
Conditions
Asthma, Health Personnel
Interventions
ABIM asthma practice improvement module
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Oct 25, 2026, 11:10 AM EDT
Completed Not applicable Interventional Results available

Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children

NCT03914547
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
REDCHiP, ATTN
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 6 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 11:10 AM EDT
Withdrawn Phase 4 Interventional

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

NCT01971047
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Regular Insulin, Humalog
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 25, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

NCT00110149
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 25, 2026, 11:10 AM EDT